《大行》花旗:藥明合聯(02268.HK)上半年淨利勝預期
花旗發表報告指,藥明合聯(02268.HK)發盈喜,按國際財務報告準則,預期上半年收入按年增長超過60%,經調整淨利潤(不含利息收入及開支)增長超過67%,淨利潤增長逾50%。表現好過市場預期上半年營收和淨利分別按年增長52%和26%。營收則符合該行預期,淨利較該行預測高出32%。
報告指,藥明合聯管理層將強勁的增長歸功於ADC產業的高客戶需求、公司擁有高市佔率的市場領導地位,以及生產設施利用率的提升。該行重申對藥明合聯「買入」評級。目標價46元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.